Replies to post #5361 on Biotech Values

[urche]

[GTCB]

I'd be surprised and disappointed if they did not issue a PR that questions had been answered and submitted to the EMEA. I don't expect much detail about the Q's or A's, however, out of deference to the decision making body. The submission would be significant in that it restarts the clock ticking on the number of days (is it 90?) allowed for the history making decision by EMEA.

Regarding partnership, I'd be surprised and disappointed if we did not hear about a European partner. In fact, I predict we will hear about that before end of 2004.

Urche

[DewDiligence]

Re: GTCB

I concur with Urche. And, yes, the EMEA has 90 days to act on the ATryn review once the clock restarts following receipt of GTCB’s answers.

Regarding an ATryn partnership, the devil is in the details… and the partner. Ideally, GTCB will be able to attract a top-tier European pharma, which would surely be a market-moving event. On the other hand, if the partner is a small-time company no one has ever heard of, don’t expect the stock price to respond favorably.

As stated previously, I’m in GTCB as a long-term investor in a “new paradigm” for biopharmaceuticals. Hence, I am less interested (but not totally disinterested) in what the news flow means for trading opportunities.